Navigation Links
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data over the weekend in Los Angeles, California at the Annual Meeting of the American Association for Cancer Research.

Abnormality of the p53 tumor suppressor is one of the most common and fundamental molecular defects in cancer. ADVEXIN's mechanism of action is targeted to restoring p53 tumor suppressor function and the detection of abnormal p53 is a logical predictive biomarker for ADVEXIN efficacy. In a study of 28 recurrent head and neck cancer patients in Phase 2 clinical trials, abnormal p53 was shown to correlate with increased survival and tumor responses following ADVEXIN treatment.

The median survival of patients with tumors expressing the abnormal p53 biomarker was 11.6 months compared to only 3.5 months in patients whose tumors had normal p53. The association between the abnormal p53 biomarker and increased survival following ADVEXIN therapy was highly statistically significant (p=0.0007).

The abnormal p53 biomarker was also associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients with the abnormal p53 biomarker compared to none (zero percent) of patients with p53 normal tumors. In addition, tumor growth control lasting for a minimum of two treatment cycles was observed in 75 percent of patients with abnormal p53 tumors compared to 27 percent of patients with a normal p53 biomarker. Both the increased reduction in tumor size and tumor growth control associated with the abnormal p53 biomarker were statistically significant (p=0.02).

Importantly, patients with abnormal p53 tumors are known to have poor responses and survival following standard treatments. These patients have the greatest need for new therapies and they achieved the most benefit from ADVEXIN t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
5. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... CITY, Calif., Dec. 18, 2014 Capnia, ... the development of medical diagnostics based on its ... gas flow, today announced financial results for the ... 2014. "Following the completion of our ... positioned to maximize the recently initiated CoSense® commercial ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... HAE ) announced that it has entered ... of Hemerus Medical, LLC, a Minnesota-based company that develops ... processing and storage of blood components.  Hemerus has completed ... Drug Application to the FDA for its unique, patented ...
... Inc. (NYSE: HRC ) invites you to listen ... Care Conference in Boston on May 8, 2012, at 8:00 ... the live discussion via the internet link at http://ir.hill-rom.com/events.cfm ... recorded replay of the discussion will be available one hour ...
Cached Medicine Technology:Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 2Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 3Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 4
(Date:12/21/2014)... (PRWEB) December 22, 2014 Weddingshe.com, an ... occasion gowns, has recently released its new selection of ... models are made according to the newest fashion trends. ... stunning dresses for cocktail parties . All of ... 80 percent off. We are making every effort to ...
(Date:12/21/2014)... Beverly Hills, Ca (PRWEB) December 21, 2014 ... Dr. Khanna was a guest at the Aspen Helicopters ... for kids and a Santa with sleigh, flown by ... the helicopter appeared invisible; only Santa with sleigh was ... both during day and night. Dr.Khanna has helped many ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding dresses was ... designs in this collection, and all of them are ... promises to provide the most fashionable designs to ... fashion trends come and go. If ladies have any ... is ready to assist. , “These new models ...
(Date:12/21/2014)... Dennis Thompson HealthDay Reporter ... find e-cigarettes less addictive than traditional cigarettes, new research finds. ... they did regular cigarettes, thousands of ex-smokers said they have ... irritable over their need to smoke, researchers reported. ... significantly less for e-cig use than for tobacco use," said ...
(Date:12/21/2014)... New York, NY (PRWEB) December 21, 2014 ... is nearing 1,400 in a consolidated litigation underway in ... court documents, a total of 1,375 claims involving the ... County Superior Court. These lawsuits were filed by women ... claim to have led to uterine perforations and other ...
Breaking Medicine News(10 mins):Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3
... prevention or delay of full-blown disease seen in treated ... Among patients who show early signs of multiple sclerosis, ... halve the risk that they will develop full-blown disease, ... who are diagnosed with multiple sclerosis first show signs ...
... , NEW YORK, Oct. 6 Metabolife, a leading brand ... -- a campaign encouraging participants to bring about positive, incremental ... simple, everyday thoughtful actions. The campaign kicked-off with the launch ... it is often the accumulation of small changes that delivers ...
... WEST BLOOMFIELD, Mich., Oct. 6 Henry Ford West Bloomfield ... disease using a state-of-the-art treatment called gene transfer. , ... able to restore better mobility in Parkinson,s patients who have ... of this clinical trial provides hope to a Parkinson,s disease ...
... HILLS, Mich., Oct. 6 Cogdell Spencer ... Cancer Center has been certified at the LEED Silver ... the first USGBC LEED Silver Certified health care facility ... Design (LEED) is an internationally recognized green building certification ...
... Pa., Oct. 6 RAM Technologies, Inc., a ... health plans, has once again been named to ... Employers in the Greater Philadelphia region. RAM ... applications that automate the administration of health benefits. ...
... have created a viable technology to improve the detection ... Quantum Interference Device (SQUID) enhanced the ability to rapidly ... a sample at least 10 fold, and increased sensitivity ... study are published in Cancer Research , a ...
Cached Medicine News:Health News:Early Drug Treatment May Cut Multiple Sclerosis Risk 2Health News:Communities Nationwide Learn 'Less Is More' from Metabolife(R) Through 1,000 In-Home Parties and An Interactive Site www.joinlessismore.com 2Health News:Communities Nationwide Learn 'Less Is More' from Metabolife(R) Through 1,000 In-Home Parties and An Interactive Site www.joinlessismore.com 3Health News:Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinson's Disease 2Health News:Botsford Hospital Cancer Center Earns Silver LEED Certification from the U.S. Green Building Council 2Health News:Botsford Hospital Cancer Center Earns Silver LEED Certification from the U.S. Green Building Council 3Health News:RAM Technologies Named to Philadelphia Business Journal's List of Top Tech Employers 2Health News:High-sensitivity bone marrow aspiration technology enhances leukemia cell detection 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: